Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 LIB Therapeutics’ LEROCHOL Receives FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

LIB Therapeutics’ LEROCHOL Receives FDA Approval

Represents an important addition to the therapeutic options for patients who struggle to meet LDL-C targets with existing treatments.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

The U.S. Food and Drug Administration (FDA) has approved LIB Therapeutics’ LEROCHOL (lerodalcibep-liga) for the treatment of adults with elevated low-density lipoprotein cholesterol (LDL-C)—marking a significant advancement in cardiovascular disease management and representing an important addition to the therapeutic options for patients who struggle to meet LDL-C targets with existing treatments.

LEROCHOL, a novel, third-generation PCSK9 inhibitor developed by LIB Therapeutics, is designed to provide robust and sustained reductions in LDL-C through a convenient, once-monthly subcutaneous administration. The approval reflects positive outcomes from the comprehensive Phase 3 LIBerate clinical program, which demonstrated meaningful lowering of LDL-C in a broad patient population, including those with heterozygous familial hypercholesterolemia and other high-risk groups.

Astrea Bioseparations, which supports the biopharmaceutical industry through the supply of critical materials, was part of the supply chain for LEROCHOL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics